In vitro targeting effect of lactoferrin modified PEGylated liposomes for hepatoma cells.
- Author:
Min-yan WEI
;
Qi ZOU
;
Chuan-bin WU
;
Yue-hong XU
- Publication Type:Journal Article
- MeSH:
Asialoglycoprotein Receptor;
metabolism;
Carcinoma, Hepatocellular;
pathology;
Coumarins;
Drug Delivery Systems;
Endocytosis;
Hep G2 Cells;
drug effects;
Humans;
Lactoferrin;
pharmacology;
Liposomes;
Liver Neoplasms;
pathology;
Particle Size;
Phosphatidylethanolamines;
Polyethylene Glycols;
Thiazoles
- From:
Acta Pharmaceutica Sinica
2015;50(10):1272-1279
- CountryChina
- Language:Chinese
-
Abstract:
A lactoferrin-containing PEGylated liposome system (Lf-PLS) was developed and tested in vitro as a hepatoma-targeting drug delivery system. PEGylated liposomes (PLS) were successfully prepared using the thin film hydration method with peglipid post insertion. Lf was covalently conjugated onto the carboxyl terminal of DSPE-PEG2000-COOH on liposomes. Coumarin-6 was used to trace Lf-PLS with fluorescence. The cellular uptake of this system was carried out in asialoglycoprotein receptor (ASGPR) positive HepG2 cells via confocal microscopy and flow cytometry. The Lf-PLS liposome was observed as spherical or oval vesicles with the particle size around 130 nm, zeta potential about -30 mV and encapsulation efficiency more than 80%. The confocal microscopy images and flow cytometry data demonstrated that Lf-PLS resulted in significantly higher cell association by ASGPR positive HepG2 cells compared to PLS. The association between Lf-PLS and cells were dependent on the concentration, time and temperature, which was inhibited by pre-incubation with excessive free Lf. The results suggest that Lf-PLS has a good targeting effect on HepG2 cells in vitro. The targeting mechanism may be related to the specific binding of Lf and ASGPR on HepG2 cells, which guides Lf-PLS to the cell surface to induce an active endocytosis process. All these results demonstrated that Lf-PLS might be a potential drug delivery system in targeting hepatocellular carcinoma, which deserves more research on its targeting ability, antitumor efficiency, and metabolism in vivo for treatment of hepatomacellular carcinoma.
